TTrialPathMatch Me to Trials
← Back to trials
RecruitingSARS-CoV-2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

Eligible age

0.5–11 yrs

Accepts

All genders

Locations

9 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to \<12 years to determine the optimal dose level per age group.

Sponsor: ModernaTX, Inc.

Where it's recruiting

California

Ontario

Florida

Miami · Miami Lakes · Tamarac

Illinois

Chicago

Michigan

Southfield

Ohio

South Euclid

Texas

Beaumont · Brownsville

Utah

South Ogden

Virginia

Richmond

Washington

Seattle

Source: ClinicalTrials.gov · NCT07808697 · last updated 2026-11-09

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of · TrialPath